Sell, Compete, or Get Left Behind: What Private Equity Consolidation Means for Your Equine Supplement Brand

In a recent piece, we walked through the wave of strategic and private equity (PE) activity reshaping the equine supplement category, from Carlyle Group's roll-up of Compana Pet Brands to Chewy's acquisition of SmartEquine to CVC Capital Partners' $300 million bet on Equine Network. The pattern is clear: Institutional capital has arrived in this space, and the competitive environment for equine supplement brands is shifting as a result. The question now isn't whether consolidation is happening. It's what you do about it.

Here is the part that matters most for the brands we work with at BSM Partners. The equine consolidation wave is neither strictly a threat nor an opportunity. It’s both, depending on how you respond. And the two viable strategic responses require almost exactly the same foundational work. 

The Acquisition Path

If a founder or management team is thinking about an exit in the next three to seven years, whether to a strategic buyer like Zoetis or Chewy, a PE platform like Carlyle, or a roll-up vehicle emerging in this space, the preparation has to start well before the letter of intent lands in your inbox. The factors that create enterprise value in an acquisition diligence process, and those that destroy it, are specific and consistent.

Claims exposure is the first place diligence teams look. Structure/function claims on equine supplement labels need to be truthful, non-misleading, and adequately substantiated. In our experience, a meaningful number of brands in this category are carrying claims that wouldn’t survive a serious legal review. For an acquirer, unsubstantiated claims are a liability. They trigger regulatory risk and post-close complications that reduce the purchase price or kill the deal entirely. Brands with a documented claims-substantiation file are valued differently.

Quality documentation is the second pillar. National Animal Supplement Council (NASC) Quality Seal certification, supplier qualification programs, batch testing records, and certificates of analysis are not just operational best practices; they are diligence documents. A buyer conducting a manufacturing review wants to see evidence that the quality systems behind the products are real and defensible. Brands that have this infrastructure built out signal lower risk.

Formulation differentiation is the third. The premium equine supplement brands that have attracted serious buyer interest had a formulation story rooted in veterinary science and decades of clinical use. Commodity formulations assembled from standard ingredients with no differentiated science story are acquirable for logistics and customer lists, but they don’t command premium multiples.

The brands that have these three pillars in order enter the sales process with leverage. Those who don’t are negotiating from a position of weakness before the first meeting.

The Independence Path

For brands that want to remain independent and compete effectively as better-resourced platforms consolidate around them, the instinct to out-market or out-spend is understandable but wrong. PE-backed and strategic-owned platforms compete on distribution reach, category domination, and marketing scale. An independent brand cannot win that game. What an independent brand can win on is scientific credibility, veterinary trust, and product integrity. 

We’ve watched this dynamic play out in the pet space, and we’re starting to see it in equine. The independent brands that are thriving aren’t trying to look like they have institutional backing. They’re leaning into the things that large, consolidated platforms are structurally bad at: deep formulation expertise, direct relationships with veterinarians and equine nutritionists, and the ability to tell a specific, compelling, science-backed product story that a roll-up brand assembled through acquisitions can’t replicate.

But that positioning is only as strong as the foundation underneath it. If the claims on your label wouldn’t survive regulatory scrutiny, the credibility story falls apart. If your quality documentation isn’t in order, the trust from veterinarians is on borrowed time. Finally, if your formulation isn’t genuinely differentiated, your brand story is bland—marketing without substance. 

The throughline between the two roads is the same: clean up claims, build the substantiation file, get the quality infrastructure right, and make the formulation story real and defensible. The brands that have put in the work will always have more options, whether the goal is to sell or to grow.

What We’re Watching

The consolidation of the equine supplement category is not at its peak. The roll-up playbook that reshaped the pet supplement category over the last decade is now being applied here. Farnam, Platinum Performance, Compana, SmartEquine, Equine Network: these are not isolated signals. They represent a structural shift in who competes for the equine consumers’ wallets, and how.

The brands that take the next 12 to 18 months to get their regulatory and quality foundations in place, build or reinforce their formulation differentiation, and think clearly about their strategic options will be in a fundamentally different position when consolidation accelerates. The brands that wait will find themselves competing against better-resourced platforms with one hand tied behind their back, or trying to run an exit process with diligence problems they didn’t know they had.

At BSM Partners, we’ve spent our careers at the intersection of animal nutrition science and the business of bringing animal health products to market. We work with equine brands at both inflection points: building toward a transaction and building to compete. If you’re thinking seriously about where your brand stands and where you want it to go, we’d like to have that conversation.

Follow us on LinkedIn for the latest updates on all things happening here at BSM Partners.

About the Authors

Neeley Bowden Lewis is a Manager of Special Services on the BSM Partners Product Innovation team. She earned her bachelor's degree in pet food production and her master's in food science. In her early career, she worked in product innovation of pet food ingredients, focusing on the development of palatability enhancers. Bowden Lewis calls Arizona home, along with her faithful canine, Allie. 

Dr. Sydney McCauley is a Board-Certified Companion Animal Nutritionist and earned both her bachelor’s and doctoral degrees at Virginia Tech in Animal and Poultry Sciences. McCauley’s research was in nutritional physiology with a focus on understanding the effects of low birth weight on glucose, fatty acid, carbohydrate, and amino acid metabolism in skeletal muscle and overall metabolic homeostasis during neonatal development.